MARKET

LPCN

LPCN

Lipocine Inc
NASDAQ
4.590
-0.010
-0.22%
Opening 12:39 01/22 EST
OPEN
4.660
PREV CLOSE
4.600
HIGH
4.700
LOW
4.510
VOLUME
22.88K
TURNOVER
--
52 WEEK HIGH
11.79
52 WEEK LOW
3.200
MARKET CAP
24.55M
P/E (TTM)
-6.0189
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LPCN last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at LPCN last week (0106-0110)?
Weekly Report · 01/13 09:36
Weekly Report: what happened at LPCN last week (1230-0103)?
Weekly Report · 01/06 09:38
Weekly Report: what happened at LPCN last week (1223-1227)?
Weekly Report · 12/30/2024 09:36
Weekly Report: what happened at LPCN last week (1216-1220)?
Weekly Report · 12/23/2024 09:38
Lipocine's LPCN 1148 Gets Fast Track Status To Treat Sarcopenia In Decompensated Cirrhosis Patients
NASDAQ · 12/17/2024 13:48
Lipocine granted FDA Fast Track Designation for LPCN 1148
TipRanks · 12/17/2024 13:06
FDA GRANTS FAST TRACK DESIGNATION TO LIPOCINE FOR LPCN 1148 AS A TREATMENT FOR SARCOPENIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
Reuters · 12/17/2024 13:00
More
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Webull offers Lipocine Inc stock information, including NASDAQ: LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.